Inj nivol relatlimab 3mg/1mg
Products billed under this code include Opdualag.
Payment limit per 3 mg/1 mg, by effective quarter, 4Q22 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Opdualag.
Payment limit per 3 mg/1 mg, by effective quarter, 4Q22 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Opdualag | E.R. Squibb & Sons, L.L.C. | 00003-7125-11 | 80 | $16,435.36 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $205.442 | −$0.069 | 3 mg/1 mg | Inj nivol relatlimab 3mg/1mg | v1, posted September 17, 2026 |
| 3Q26 | $205.511 | +$3.756 | 3 mg/1 mg | Inj nivol relatlimab 3mg/1mg | v1, posted September 15, 2026 |
| 2Q26 | $201.755 | +$0.101 | 3 mg/1 mg | Inj nivol relatlimab 3mg/1mg | v1, posted September 15, 2026 |
| 1Q26 | $201.654 | +$3.822 | 3 mg/1 mg | Inj nivol relatlimab 3mg/1mg | v1, posted September 15, 2026 |
| 4Q25 | $197.832 | +$0.184 | 3 mg/1 mg | Inj nivol relatlimab 3mg/1mg | v1, posted September 8, 2026 |
| 3Q25 | $197.648 | +$3.571 | 3 mg/1 mg | Inj nivol relatlimab 3mg/1mg | v1, posted March 10, 2026 |
| 2Q25 | $194.077 | +$0.213 | 3 mg/1 mg | Inj nivol relatlimab 3mg/1mg | v1, posted March 10, 2026 |
| 1Q25 | $193.864 | +$3.403 | 3 mg/1 mg | Inj nivol relatlimab 3mg/1mg | v1, posted December 19, 2025 |
| 4Q24 | $190.461 | −$0.034 | 3 mg/1 mg | Inj nivol relatlimab 3mg/1mg | v1, posted June 11, 2025 |
| 3Q24 | $190.495 | +$3.492 | 3 mg/1 mg | Inj nivol relatlimab 3mg/1mg | v1, posted June 11, 2025 |
| 2Q24 | $187.003 | −$0.15 | 3 mg/1 mg | Inj nivol relatlimab 3mg/1mg | v1, posted March 11, 2025 |
| 1Q24 | $187.153 | +$3.536 | 3 mg/1 mg | Inj nivol relatlimab 3mg/1mg | v1, posted December 19, 2024 |
| 4Q23 | $183.617 | −$0.013 | 3 mg/1 mg | Inj nivol relatlimab 3mg/1mg | v1, posted October 10, 2024 |
| 3Q23 | $183.63 | +$3.292 | 3 mg/1 mg | Inj nivol relatlimab 3mg/1mg | v1, posted June 5, 2024 |
| 2Q23 | $180.338 | −$0.046 | 3 mg/1 mg | Inj nivol relatlimab 3mg/1mg | v1, posted February 23, 2024 |
| 1Q23 | $180.384 | −$0.258 | 3 mg/1 mg | Inj nivol relatlimab 3mg/1mg | v1, posted December 6, 2023 |
| 4Q22 | $180.642 | – | 3 mg/1 mg | Inj nivol relatlimab 3mg/1mg | v1, posted June 22, 2023 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.